Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC decreased its position in Omnicell, Inc. (NASDAQ:OMCL) by 57.3% in the first quarter, HoldingsChannel.com reports. The fund owned 134,498 shares of the company’s stock after selling 180,237 shares during the period. Trillium Asset Management LLC’s holdings in Omnicell were worth $3,931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Benjamin Edwards Inc. raised its stake in Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after acquiring an additional 868 shares during the last quarter. Strs Ohio raised its stake in Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after acquiring an additional 1,100 shares during the last quarter. Entropy Technologies LP purchased a new position in Omnicell in the 1st quarter worth $227,000. ProShare Advisors LLC raised its stake in Omnicell by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after acquiring an additional 626 shares during the last quarter. Finally, Aristides Capital LLC purchased a new position in Omnicell in the 4th quarter worth $269,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of NASDAQ OMCL remained flat at $27.52 during trading on Friday. The company’s stock had a trading volume of 368,457 shares, compared to its average volume of 520,873. The company has a 50-day moving average price of $28.92 and a two-hundred day moving average price of $29.43. The firm has a market cap of $1.26 billion, a PE ratio of -59.83, a P/E/G ratio of 101.63 and a beta of 0.80. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $66.65. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The business had revenue of $246.15 million during the quarter, compared to analyst estimates of $235.70 million. As a group, research analysts expect that Omnicell, Inc. will post 0.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Benchmark restated a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research note on Monday. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $42.20.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.